1. Home
  2. UGRO vs INDP Comparison

UGRO vs INDP Comparison

Compare UGRO & INDP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo urban-gro Inc.

UGRO

urban-gro Inc.

HOLD

Current Price

$0.35

Market Cap

3.0M

ML Signal

HOLD

Logo Indaptus Therapeutics Inc.

INDP

Indaptus Therapeutics Inc.

HOLD

Current Price

$1.95

Market Cap

4.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
UGRO
INDP
Founded
2014
2000
Country
United States
United States
Employees
N/A
N/A
Industry
Industrial Specialties
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.0M
4.0M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
UGRO
INDP
Price
$0.35
$1.95
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$3.00
N/A
AVG Volume (30 Days)
13.8M
35.1K
Earning Date
03-27-2026
11-12-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$59,985,138.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$28.40
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.21
$1.65
52 Week High
$1.19
$47.60

Technical Indicators

Market Signals
Indicator
UGRO
INDP
Relative Strength Index (RSI) 59.58 36.65
Support Level $0.30 $2.39
Resistance Level $0.49 $2.94
Average True Range (ATR) 0.07 0.20
MACD 0.02 -0.01
Stochastic Oscillator 47.64 2.62

Price Performance

Historical Comparison
UGRO
INDP

About UGRO urban-gro Inc.

Urban-gro Inc is an integrated professional services and construction design-build firm. Its business focuses predominantly on providing fee-based knowledge-based services as well as the value-added reselling of equipment. The company offers value-added architectural, engineering, systems procurement and integration, and construction design-build solutions to customers operating in the controlled environment agriculture (CEA) and industrial and other commercial (Commercial) sectors. It derives revenue predominately from the sale of equipment systems, services, construction design-build, and other various immaterial contracts with customers.

About INDP Indaptus Therapeutics Inc.

Indaptus Therapeutics Inc is a pre-clinical biotechnology company engaged in developing a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. It has developed a proprietary platform that exploits bacteria's natural ability to activate both innate and adaptive cellular immune pathways. The company's clinical candidate Decoy20, has the ability to elicit single-agent activity and durable anti-tumor responses in the combination setting against colorectal, hepatocellular, pancreatic carcinoma, and non-Hodgkin's lymphoma models.

Share on Social Networks: